AbCellera Biologics Inc. (ABCL) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. AbCellera Biologics Inc. is a biotechnology company focused on antibody drug discovery and development. The company operates an "engine" to discover antibodies for partners and develops its own internal pipeline. As of August 1, 2024, the company had 294,665,532 common shares outstanding.
Key Financial Metrics
| Metric (in thousands, except per share) | Q2 2024 | Q2 2023 | YTD 6 Months 2024 | YTD 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $7,323 | $10,056 | $17,277 | $22,248 |
| Net Loss | $(36,930) | $(30,528) | $(77,540) | $(70,638) |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.11) | $(0.26) | $(0.24) |
| Cash, Cash Equivalents & Marketable Securities | $670,356 | $760,585 (Dec 31, 2023) | $670,356 | $760,585 (Dec 31, 2023) |
| Operating Cash Flow (6 Months) | $(71,674) | $(24,160) | $(71,674) | $(24,160) |
Note: Revenue consists of research fees, licensing revenue, and milestone payments. The company does not currently generate significant recurring royalty revenue following the discontinuation of COVID-19 antibody sales by partners.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 27% in Q2 2024 compared to Q2 2023, driven primarily by a 45% drop in research fees due to the timing of partner program execution. This was partially offset by $1.5 million in milestone payments recognized in Q2 2024.
- Significant Impairment Charge: Depreciation, amortization, and impairment expenses surged 551% in Q2 2024 to $36.5 million (from $5.6 million in Q2 2023). This was primarily due to a full impairment charge of $32.0 million related to In-Process Research and Development (IPR&D) assets acquired from TetraGenetics, resulting from portfolio prioritization.
- Non-Cash Gain: The impairment of the TetraGenetics IPR&D assets corresponded with a $32.4 million non-cash fair value gain on contingent consideration liabilities, recorded in "Other (income) expense."
- Operating Expenses: Research and Development (R&D) expenses increased 12% in Q2 2024 year-over-year, reflecting continued investment in the discovery engine and internal programs. General and Administrative (G&A) expenses increased 30% due to higher legal and software costs.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, marketable securities, and anticipated government contributions are sufficient to fund operations and capital expenditures for at least the next 36 months.
- Recent Developments:
- Announced an expanded collaboration with Eli Lilly in immunology, cardiovascular disease, and neuroscience (July 31, 2024).
- Partner Invetx announced an acquisition by Dechra Pharmaceuticals for up to $520 million; AbCellera holds a royalty stake and equity position in Invetx.
- Key Risks:
- Profitability: The company has incurred losses since inception and may not achieve profitability. Revenue is highly dependent on partner milestones and commercialization, which are uncertain.
- Intellectual Property Litigation: Ongoing patent infringement litigation against Bruker Cellular Analysis and a civil lawsuit involving the Estate of John Schrader pose potential financial and operational risks.
- Government Contributions: Significant funding from the Government of Canada and British Columbia is subject to covenants, including restrictions on dividends and requirements for capital expenditures and headcount in Canada.
Investor Verification Checklist
- Impairment Details: Verify the specific impact of the $32.0 million TetraGenetics IPR&D impairment on future R&D capabilities and the corresponding reduction in contingent consideration liabilities.
- Revenue Visibility: Assess the pipeline of partner-initiated programs (93 cumulative starts) and the timeline for future milestone payments, given the 27% revenue decline.
- Litigation Status: Monitor the progress of the patent litigation against Bruker Cellular Analysis and the Schrader estate, as adverse outcomes could impact IP protection and financial results.
- Government Funding Covenants: Review compliance with the Strategic Innovation Fund (SIF) and other government contribution agreements, specifically regarding capital expenditure targets and dividend restrictions.
- Cash Burn Rate: Evaluate the sustainability of the current operating cash burn (~$71.7 million for 6 months) against the $670 million liquidity position to confirm the 36-month runway.